Products

SFL Pharma places prescription drugs onto the Swiss market, with a special focus on orphan drugs. Rare (or "orphan") diseases are life-threatening or chronically debilitating diseases that occur in less than 5 in 10,000 people in the Swiss community. There are approximately 7,000 rare diseases that may affect around 500,000 people in Switzerland.

Galafold

Lysosomal Storage Disorders

Among orphan diseases, lysosomal storage disorders (LSD) pose a subgroup of 50 rare, medical conditions that affect approximately 10,000 people worldwide. LSDs are inherited metabolic disorders that are caused by a lack of specific enzymes that are responsible for the disposal of cellular substances in so-called lysosomes. As a result, these substances accumulate and cause toxicity in different organ systems such as kidney, muscle, lung, heart and brain. LSDs are severe, life-threatening diseases and put a heavy burden on patients, their caregivers and the healthcare system.

The visiting, browsing and use of this website are the sole and absolute responsibility of the website visitor. SFL Pharma accepts no duty of care or liability of any kind whatsoever to any such visitor, and no responsibility for damages, if any, suffered by any website visitor as a result of decisions made, or not made, or actions taken, or not taken, based on this website. The use of this website is governed by the laws of Switzerland and, for all disputes in relation to this website, the courts of the canton of Basel-City have exclusive jurisdiction.